-
1
-
-
38149142887
-
-
world Health Organization, Geneva, Switzerland [Last accessed 17 January 2013]
-
Diabetes fact sheet. world Health Organization, Geneva, Switzerland; 2012. Available from: http://www.who. int/mediacentre/factsheets/fs312/en/index. html [Last accessed 17 January 2013].
-
(2012)
Diabetes Fact Sheet
-
-
-
3
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
-
Turner R, Homan R, Cull A. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.
-
(1998)
Lancet
, vol.352
, Issue.9131
, pp. 837-853
-
-
Turner, R.1
Homan, R.2
Cull, A.3
-
4
-
-
58149389215
-
Glucose control and vascular complications in veterans with type 2 diabetes
-
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39.
-
(2009)
N Engl J Med
, vol.360
, Issue.2
, pp. 129-139
-
-
Duckworth, W.1
Abraira, C.2
Moritz, T.3
-
5
-
-
84864270406
-
Basal insulin and cardiovascular and other outcomes in dysglycemia
-
Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367(4):319-28.
-
(2012)
N Engl J Med
, vol.367
, Issue.4
, pp. 319-328
-
-
Gerstein, H.C.1
Bosch, J.2
Dagenais, G.R.3
-
6
-
-
45149131667
-
Effects of intensive glucose lowering in type 2 diabetes
-
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59.
-
(2008)
N Engl J Med
, vol.358
, Issue.24
, pp. 2545-2559
-
-
Gerstein, H.C.1
Miller, M.E.2
Byington, R.P.3
-
7
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72.
-
(2008)
N Engl J Med
, vol.358
, Issue.24
, pp. 2560-2572
-
-
Patel, A.1
MacMahon, S.2
Chalmers, J.3
-
8
-
-
0042991484
-
Implications of the United kingdom prospective diabetes study
-
Genuth S, Eastman R, Kahn R, et al. Implications of the United kingdom prospective diabetes study. Diabetes Care 2003;26(Suppl 1):S28-32.
-
(2003)
Diabetes Care
, vol.26
, Issue.SUPPL. 1
-
-
Genuth, S.1
Eastman, R.2
Kahn, R.3
-
9
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79.
-
(2012)
Diabetes Care
, vol.35
, Issue.6
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
10
-
-
35348891586
-
Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells
-
Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007(106):S27-35.
-
(2007)
Kidney Int Suppl
, vol.106
-
-
Lee, Y.J.1
Han, H.J.2
-
11
-
-
75149196250
-
Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
-
Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95(1):34-42.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, Issue.1
, pp. 34-42
-
-
Nair, S.1
Wilding, J.P.2
-
12
-
-
4344559467
-
The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function
-
Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 2004;28(5):364-71.
-
(2004)
JPEN J Parenter Enteral Nutr
, vol.28
, Issue.5
, pp. 364-371
-
-
Scheepers, A.1
Joost, H.G.2
Schurmann, A.3
-
13
-
-
0033870323
-
T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats
-
Adachi T, Yasuda K, Okamoto Y, et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 2000;49(8):990-5.
-
(2000)
Metabolism
, vol.49
, Issue.8
, pp. 990-995
-
-
Adachi, T.1
Yasuda, K.2
Okamoto, Y.3
-
14
-
-
48249146624
-
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
-
Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57(6):1723-9.
-
(2008)
Diabetes
, vol.57
, Issue.6
, pp. 1723-1729
-
-
Han, S.1
Hagan, D.L.2
Taylor, J.R.3
-
15
-
-
33845873376
-
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
-
Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320(1):323-30.
-
(2007)
J Pharmacol Exp Ther
, vol.320
, Issue.1
, pp. 323-330
-
-
Katsuno, K.1
Fujimori, Y.2
Takemura, Y.3
-
16
-
-
84857099986
-
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models
-
Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012;7:e30555.
-
(2012)
PLoS One
, vol.7
-
-
Liang, Y.1
Arakawa, K.2
Ueta, K.3
-
17
-
-
77956319973
-
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus
-
Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53(17):6355-60.
-
(2010)
J Med Chem
, vol.53
, Issue.17
, pp. 6355-6360
-
-
Nomura, S.1
Sakamaki, S.2
Hongu, M.3
-
18
-
-
12744253796
-
Phlorizin: A review
-
Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21(1):31-8.
-
(2005)
Diabetes Metab Res Rev
, vol.21
, Issue.1
, pp. 31-38
-
-
Ehrenkranz, J.R.1
Lewis, N.G.2
Kahn, C.R.3
Roth, J.4
-
19
-
-
0023275573
-
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
-
Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79(5):1510-15.
-
(1987)
J Clin Invest
, vol.79
, Issue.5
, pp. 1510-1515
-
-
Rossetti, L.1
Smith, D.2
Shulman, G.I.3
-
20
-
-
84877867249
-
Advisory committee briefing materials: Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus
-
Janssen Research & Development LLC. Advisory committee briefing materials: Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. Endocrinologic and Metabolic Drugs Advisory Committee 2012. p. 1-184.
-
(2012)
Endocrinologic and Metabolic Drugs Advisory Committee
, pp. 1-184
-
-
Research, J.1
Llc, D.2
-
21
-
-
84877847032
-
-
National Center For Biotechnology Information; U.S. National Library Of Medicine Bethesda MD Last Accessed 21 March 2013
-
Canagliflozin - compound summary. National Center for Biotechnology Information; U.S. National Library of Medicine, Bethesda, MD; 2008. Available from: http://pubchem. ncbi.nlm.nih.gov/summary/summary.cgicid=24812758 [Last accessed 21 March 2013].
-
(2008)
Canagliflozin - Compound Summary
-
-
-
22
-
-
83655184724
-
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT- 2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors
-
Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT- 2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14(1):83-90.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.1
, pp. 83-90
-
-
Grempler, R.1
Thomas, L.2
Eckhardt, M.3
-
23
-
-
84860252876
-
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
-
Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14(6):539-45.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.6
, pp. 539-545
-
-
Devineni, D.1
Morrow, L.2
Hompesch, M.3
-
24
-
-
84877865378
-
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized placebo-controlled study
-
Published Online 14 February 2013; doi: 10.2337/dc12-2391
-
Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013; published online 14 February 2013; doi: 10.2337/dc12-2391.
-
(2013)
Diabetes Care
-
-
Polidori, D.1
Sha, S.2
Mudaliar, S.3
-
25
-
-
79956331954
-
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
-
Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13(7):669-72.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.7
, pp. 669-672
-
-
Sha, S.1
Devineni, D.2
Ghosh, A.3
-
26
-
-
80052890663
-
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (sglt2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects [abstract]
-
[Last accessed 17 January 2013]
-
Sarich T, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (sglt2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects [abstract]. Diabetes 2010;59(Suppl 1). Available from: http://professional.diabetes.org/Abstracts- Display.aspxTYP=1&CID=79515 [Last accessed 17 January 2013].
-
(2010)
Diabetes
, vol.59
, Issue.SUPPL. 1
-
-
Sarich, T.1
Devineni, D.2
Ghosh, A.3
-
27
-
-
79952984824
-
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated [abstract]
-
[Last accessed 17 January 2013]
-
Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated [abstract]. Diabetes 2010;59(Suppl 1). Available from: http://professional.diabetes.org/Abstracts-Display.aspxTYP= 1&CID=79516 [Last accessed 17 January 2013].
-
(2010)
Diabetes
, vol.59
, Issue.SUPPL. 1
-
-
Sha, S.1
Devineni, D.2
Ghosh, A.3
-
28
-
-
0015122757
-
Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects
-
Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28(1):101-9.
-
(1971)
Scand J Clin Lab Invest
, vol.28
, Issue.1
, pp. 101-109
-
-
Mogensen, C.E.1
-
29
-
-
33748064644
-
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study
-
Rave K, Nosek L, Posner J, et al. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 2006;21(8):2166-71.
-
(2006)
Nephrol Dial Transplant
, vol.21
, Issue.8
, pp. 2166-2171
-
-
Rave, K.1
Nosek, L.2
Posner, J.3
-
30
-
-
80052084915
-
Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes [abstract]
-
[Last accessed 17 January 2013]
-
Polidori D, Zhao Y, Sha S, Canovatchel W. Canagliflozin treatment improves beta cell function in subjects with type 2 diabetes [abstract]. Diabetes 2010;59(Suppl 1). Available from: http://professional.diabetes.org/ Abstracts-Display.aspxTYP=1&CID=79592 [Last accessed 17 January 2013].
-
(2010)
Diabetes
, vol.59
, Issue.SUPPL. 1
-
-
Polidori, D.1
Zhao, Y.2
Sha, S.3
Canovatchel, W.4
-
31
-
-
84877844057
-
Lack of clinically meaningful interaction between canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, and digoxin or warfarin in healthy subjects [abstract]
-
Devineni D, Manitpisitkul P, Vaccaro N, et al. Lack of clinically meaningful interaction between canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, and digoxin or warfarin in healthy subjects [abstract]. Clin Pharmacol Drug Dev 2012;1:81.
-
(2012)
Clin Pharmacol Drug Dev
, vol.1
, pp. 81
-
-
Devineni, D.1
Manitpisitkul, P.2
Vaccaro, N.3
-
32
-
-
80052813670
-
The effects of multiple doses of canagliflozin on the pharmacokinetics and safety of single doses of an oral contraceptive containing ethinyl estradiol and levonorgestrel [abstract]
-
Skee D, Shalayda K, Vandebosch A, et al. The effects of multiple doses of canagliflozin on the pharmacokinetics and safety of single doses of an oral contraceptive containing ethinyl estradiol and levonorgestrel [abstract]. Clin Pharmacol Ther 2010;87(Suppl 1):S35.
-
(2010)
Clin Pharmacol Ther
, vol.87
, Issue.SUPPL. 1
-
-
Skee, D.1
Shalayda, K.2
Vandebosch, A.3
-
33
-
-
85058631060
-
Effects of Canagliflozin on the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Metformin and Glyburide [abstract]
-
San Diego CA
-
Devineni D, Sarich TC, Wexler D, et al. Effects of canagliflozin on the pharmacokinetics (PK) and pharmacodynamics (PD) of metformin and glyburide [abstract]. American Diabetes Association 71st Scientific Sessions. San Diego, CA; 2011.
-
(2011)
American Diabetes Association 71st Scientific Sessions
-
-
Devineni, D.1
Sarich, T.C.2
Wexler, D.3
-
34
-
-
84874291673
-
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
-
Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 372-382
-
-
Stenlof, K.1
Cefalu, W.T.2
Kim, K.A.3
-
35
-
-
84861781220
-
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
-
Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35(6):1232-8.
-
(2012)
Diabetes Care
, vol.35
, Issue.6
, pp. 1232-1238
-
-
Rosenstock, J.1
Aggarwal, N.2
Polidori, D.3
-
36
-
-
84880005461
-
Efficacy and safety of canagliflozin a sodium glucose co-transporter 2 inhibitor compared with glimepiride in patients with type 2 diabetes on background metformin [abstract]
-
Philadelphia PA
-
Cefalu WT, Leiter LA, Niskanen L, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [abstract]. American Diabetes Association 72nd Scientific Sessions. Philadelphia, PA; 2012.
-
(2012)
American Diabetes Association 72nd Scientific Sessions
-
-
Cefalu, W.T.1
Leiter, L.A.2
Niskanen, L.3
-
38
-
-
84875168195
-
Canagliflozin (CANA) A Sodium Glucose Co-transporter 2 Inhibitor Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes (T2D) Inadequately Controlled with Metformin (MET) and Sulfonylurea (SU) [abstract]
-
Philadelphia PA
-
Wilding JP, Mathieu C, Vercruysse F, et al. Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU) [abstract]. American Diabetes Association 72nd Scientific Sessions. Philadelphia, PA; 2012.
-
(2012)
American Diabetes Association 72nd Scientific Sessions
-
-
Wilding, J.P.1
Mathieu, C.2
Vercruysse, F.3
-
39
-
-
84885360883
-
Efficacy and Safety of Canagliflozin A Sodium Glucose Co-transporter 2 Inhibitor Compared with Sitagliptin in Patients with Type 2 Diabetes on Metformin Plus Sulfonylurea [abstract]
-
Philadelphia PA
-
Gross J, Schernthaner G, Fu M, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulfonylurea [abstract]. American Diabetes Association 72nd Scientific Sessions. Philadelphia, PA; 2012.
-
(2012)
American Diabetes Association 72nd Scientific Sessions
-
-
Gross, J.1
Schernthaner, G.2
Fu, M.3
-
40
-
-
84877855570
-
Efficacy and Safety of Canagliflozin (CANA) An Inhibitor of Sodium Glucose Co-transporter 2 (SGLT2) Added-on to Insulin Therapy +- Oral Agents in Type 2 Diabetes [abstract]
-
Berlin Germany
-
Matthews DR, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes [abstract]. 48th European Association for the Study of Diabetes Annual Meeting. Berlin, Germany; 2012.
-
(2012)
48th European Association for the Study of Diabetes Annual Meeting
-
-
Matthews, D.R.1
Fulcher, G.2
Perkovic, V.3
-
41
-
-
84877866941
-
Efficacy and Safety of Canagliflozin (CANA) A Sodium Glucose Co-transporter 2 Inhibitor (SGLT2) in Older Subjects with Type 2 Diabetes Mellitus [abstract]
-
Berlin Germany
-
Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor (SGLT2), in older subjects with type 2 diabetes mellitus [abstract]. 48th European Association for the Study of Diabetes Annual Meeting. Berlin, Germany; 2012.
-
(2012)
48th European Association for the Study of Diabetes Annual Meeting
-
-
Bode, B.1
Stenlof, K.2
Sullivan, D.3
-
42
-
-
84876311251
-
Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes and Chronic Kidney Disease
-
Published Online 06 Mar 2013; doi: 10.1111/dom.12090
-
Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; published online 06 Mar 2013; doi: 10.1111/dom.12090.
-
(2013)
Diabetes Obes Metab
-
-
Yale, J.-F.1
Bakris, G.2
Cariou, B.3
-
43
-
-
84863617006
-
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor
-
Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012;28(7):1173-8.
-
(2012)
Curr Med Res Opin
, vol.28
, Issue.7
, pp. 1173-1178
-
-
Nyirjesy, P.1
Zhao, Y.2
Ways, K.3
Usiskin, K.4
-
44
-
-
84877845736
-
-
U.S. Food and Drug Administration, Silver Spring, Maryland [Last accessed 17 January 2013]
-
Endocrinologic and metabolic drugs advisory committee meeting announcement. U.S. Food and Drug Administration, Silver Spring, Maryland; 2013. Available from: http://www.fda. gov/AdvisoryCommittees/Calendar/ucm331503.htm [Last accessed 17 January 2013].
-
(2013)
Endocrinologic and Metabolic Drugs Advisory Committee Meeting Announcement
-
-
-
46
-
-
84869998632
-
Dapagliflozin: A review of its use in type 2 diabetes mellitus
-
Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs 2012;72(17):2289-312.
-
(2012)
Drugs
, vol.72
, Issue.17
, pp. 2289-2312
-
-
Plosker, G.L.1
|